T1	Intervention 820 1062	receive intravenous ganitumab 12 mg per kg bodyweight or placebo in combination with open-label intramuscular fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days) or oral exemestane (25 mg once daily) on a 28-day cycle
T2	Intervention 1164 1200	Response was assessed every 8 weeks.
